Metabolic syndrome (MetS) is a cluster of risk factors that increase the likelihood of developing cardiovascular, metabolic and other diseases. The pharmacological management of MetS often involves polypharmacy, making it essential to understand how drug-metabolising enzymes, transporters, transcription factors and other proteins involved are affected under different metabolic conditions. This study investigated the relative mRNA expression of key hepatic and intestinal genes involved in drug metabolism, including Cyp1a2, Cyp3a23, Cyp2d1, Cyp2c11, Cyp2c6, Cyp2e1, Cyp7a1, Cyp2b1, Cyp2a1, Abcg5, Abcg8, Abcb1, Nr1i3, Nr1i2, Ahr, Gsta1 and Comt, in four nonobese rat models of MetS: hereditary hypertriglyceridaemic (HHTg), spontaneously hypertensive rat (SHR), SHR expressing transgenic human C-reactive protein (SHR-CRP), and bilaterally ovariectomised Wistar (W-OVX), compared to Wistar controls. Gene expression was quantified by RT-PCR with data normalised using the ΔΔCt method. Between the models studied, measurements showed significant differences in the liver. The upregulation of Cyp2c6 and Cyp3a23 was observed only in SHR; upregulated Cyp2d1 was found in SHR as well as in HHTg rats. The downregulated Cyp1a2 was measured in a condition of hypertriglyceridemia, postmenopause or hypertension. These findings highlight model-specific alterations in gene expression that may affect drug metabolism and interactions. The HHTg may be, in particular, a suitable model for preclinical studies focusing on intestinal drug-drug interactions in MetS-related conditions.

Centre for Experimental Medicine Institute for Clinical and Experimental Medicine Prague Czech Republic

Department of Microbiology at the Faculty of Medicine and Dentistry Palacky University Olomouc Olomouc Czech Republic

Department of Pharmacology at the Faculty of Medicine and Dentistry Palacky University Olomouc Olomouc Czech Republic

See more in PubMed

Alemany M., “The Metabolic Syndrome, a Human Disease,” International Journal of Molecular Sciences 25 (2024): 2251. PubMed PMC

Hossam Abdelmonem B., Abdelaal N. M., Anwer E. K. E., et al., “Decoding the Role of CYP450 Enzymes in Metabolism and Disease: A Comprehensive Review,” Biomedicines 12 (2024): 1467. PubMed PMC

Saklayen M. G., “The Global Epidemic of the Metabolic Syndrome,” Current Hypertension Reports 20 (2018): 12, 10.1007/S11906-018-0812-Z. PubMed DOI PMC

Cheng L. S., Naqiah Hairi N., and Ming Moy F., “Metabolic Syndrome Among Non‐Obese Adults in the Teaching Profession in Melaka, Malaysia,” Journal of Epidemiology 27 (2017): 130–134. PubMed PMC

Wildman R. P., Muntner P., Reynolds K., et al., “The Obese Without Cardiometabolic Risk Factor Clustering and the Normal Weight With Cardiometabolic Risk Factor Clustering: Prevalence and Correlates of 2 Phenotypes Among the US Population (NHANES 1999–2004),” Archives of Internal Medicine 168, no. 15 (2008): 1617–1624. PubMed

Lillich F. F., Imig J. D., and Proschak E., “Multi‐Target Approaches in Metabolic Syndrome,” Frontiers in Pharmacology 11, no. 1996 (2021): 1–18, 10.3389/fphar.2020.554961. PubMed DOI PMC

Zarezadeh M., Saedisomeolia A., Shekarabi M., Khorshidi M., Emami M. R., and Müller D. J., “The Effect of Obesity, Macronutrients, Fasting and Nutritional Status on Drug‐Metabolizing Cytochrome P450s: A Systematic Review of Current Evidence on Human Studies,” European Journal of Nutrition 2020 60, no. 6 (2020): 2905–2921. PubMed

Konstandi M. and Johnson E. O., “Age‐Related Modifications in CYP‐Dependent Drug Metabolism: Role of Stress,” Front Endocrinol (Lausanne). 14 (2023): 1–10, 10.3389/FENDO.2023.1143835. PubMed DOI PMC

Tabur S., Oztuzcu S., Oguz E., et al., “CYP Gene Expressions in Obesity‐Associated Metabolic Syndrome,” Obesity Research & Clinical Practice 10 (2016): 719–723. PubMed

He Y., Yang T., Du Y., et al., “High Fat Diet Significantly Changed the Global Gene Expression Profile Involved in Hepatic Drug Metabolism and Pharmacokinetic System in Mice,” Nutrition & Metabolism (London) 17 (2020): 1–15, 10.1186/S12986-020-00456-W. PubMed DOI PMC

Xia C., Zhang X., Cao T., et al., “Hepatic Transcriptome Analysis Revealing the Molecular Pathogenesis of Type 2 Diabetes Mellitus in Zucker Diabetic Fatty Rats,” Frontiers in Endocrinology (Lausanne) 11 (2020): 565858. PubMed PMC

LaBranche T. P., Kopec A. K., Mantena S. R., et al., “Zucker Lean Rats With Hepatic Steatosis Recapitulate Asymptomatic Metabolic Syndrome and Exhibit Greater Sensitivity to Drug‐Induced Liver Injury Compared With Standard Nonclinical Sprague‐Dawley Rat Model,” Toxicologic Pathology 48 (2020): 994–1007. PubMed

Wang A. N., Carlos J., Fraser G. M., and McGuire J. J., “Zucker Diabetic‐Sprague Dawley (ZDSD) Rat: Type 2 Diabetes Translational Research Model,” Experimental Physiology 107 (2022): 265–282. PubMed PMC

Kaji N., Takagi Y., Matsuda S., Takahashi A., Fujio S., and Asai F., “Effects of Liraglutide on Metabolic Syndrome in WBN/Kob Diabetic Fatty Rats Supplemented with a High‐Fat Diet,” Animal Models and Experimental Medicine 3, no. 1 (2020): 62–68. PubMed PMC

Gimenes G. M., Santana G. O., Scervino M. V. M., Curi R., and Pereira J. N. B., “A Short Review on the Features of the Non‐Obese Diabetic Goto‐Kakizaki Rat Intestine,” Brazilian Journal of Medical and Biological Research 55, no. e11910 (2022): 1–10. PubMed PMC

Vrána A. and Kazdová L., “The Hereditary Hypertriglyceridemic Nonobese Rat: An Experimental Model of Human Hypertriglyceridemia,” Transplantation Proceedings 22 (1990): 2579. PubMed

Kazdová L., Žák A., and Vrána A., “Increased Lipoprotein Oxidability and Aortic Lipid Peroxidation in an Experimental Model of Insulin Resistance Syndromea,” Annals of the New York Academy of Sciences 827 (1997): 521–525. PubMed

Vrána A. and Kazdová L., “Increased Adipose Tissue Lipolysis in a Hypertriglyceridemic Rat Linea,” Annals of the New York Academy of Sciences 827 (1997): 510–513. PubMed

Zicha J., Pecháňová O., Čačányiová S., et al., “Hereditary Hypertriglyceridemic Rat: A Suitable Model of Cardiovascular Disease and Metabolic Syndrome?,” Physiological Research 55 (2006): 49–63. PubMed

Žourek M., Kyselová P., Mudra J., et al., “The Relationship Between Glycemia, Insulin and Oxidative Stress in Hereditary Hypertriglyceridemic Rat,” Physiological Research 57, no. 4 (2008): 531. PubMed

Li Y., Xie D., Li L., and Jiang P., “Comprehensive Analysis of Metabolic Changes in Spontaneously Hypertensive Rats,” Clinical and Experimental Hypertension 45, no. 1 (2023): 1–15, 10.1080/10641963.2023.2190529. PubMed DOI

Kwitek A. E., “Rat Models of Metabolic Syndrome,” Methods in Molecular Biology 2018 (2019): 269. PubMed PMC

Holjak E. J. B., Savinova I., Nelson V. L., et al., “An Evaluation of Cardiac Health in the Spontaneously Hypertensive Rat Colony: Implications of Evolutionary Driven Increases in Concentric Hypertrophy,” American Journal of Hypertension 35 (2021): 264–271. PubMed PMC

Li J., Kemp B. A., Howell N. L., et al., “Metabolic Changes in Spontaneously Hypertensive Rat Hearts Precede Cardiac Dysfunction and Left Ventricular Hypertrophy,” Journal of the American Heart Association 8 no. 4 (2019): e010926, 10.1161/JAHA.118.010926. PubMed DOI PMC

Gawryś‐Kopczyńska M., Szudzik M., Samborowska E., et al., “Spontaneously Hypertensive Rats Exhibit Increased Liver Flavin Monooxygenase Expression and Elevated Plasma TMAO Levels Compared to Normotensive and Ang II‐Dependent Hypertensive Rats,” Frontiers in Physiology 15 (2024): 1340166, 10.3389/fphys.2024.1340166. PubMed DOI PMC

Pepys M. B. and Hirschfield G. M., “C‐Reactive Protein: A Critical Update,” Journal of Clinical Investigation 111 (2003): 1805–1812. PubMed PMC

Pravenec M., Kajiya T., Zídek V., et al., “Effects of Human C‐Reactive Protein on Pathogenesis of Features of the Metabolic Syndrome,” Hypertension 57 (2011): 731–737. PubMed PMC

Nemeckova I., Eissazadeh S., Rathouska J. U., et al., “Transgenic Human C‐Reactive Protein Affects Oxidative Stress but Not Inflammation Biomarkers in the Aorta of Spontaneously Hypertensive Rats,” BMC Cardiovascular Disorders 24 (2024): 211, 10.1186/S12872-024-03870-7. PubMed DOI PMC

Mumusoglu S. and Yildiz B. O., “Metabolic Syndrome During Menopause,” Current Vascular Pharmacology 17 (2018): 595–603. PubMed

Pu D., Tan R., Yu Q., and Wu J., “Metabolic Syndrome in Menopause and Associated Factors: A Meta‐Analysis,” Climacteric 20 (2017): 583–591. PubMed

Malinská H., Hüttl M., Miklánková D., et al., “Ovariectomy‐Induced Hepatic Lipid and Cytochrome P450 Dysmetabolism Precedes Serum Dyslipidemia,” International Journal of Molecular Sciences 22 (2021): 4527. PubMed PMC

Medina‐Contreras J., Villalobos‐Molina R., Zarain‐Herzberg A., and Balderas‐Villalobos J., “Ovariectomized Rodents as a Menopausal Metabolic Syndrome Model. A Minireview,” Molecular and Cellular Biochemistry 475 (2020): 261–276. PubMed

Santos‐Marcos J. A., Perez‐Jimenez F., and Camargo A., “The Role of Diet and Intestinal Microbiota in the Development of Metabolic Syndrome,” Journal of Nutritional Biochemistry 70 (2019): 1–27. PubMed

Škop V., Trnovská J., Oliyarnyk O., et al., “Hepatotoxic Effects of Fenofibrate in Spontaneously Hypertensive Rats Expressing Human C‐Reactive Protein,” Physiological Research 65 (2016): 891–899, 10.33549/physiolres.933304. PubMed DOI

Tveden‐Nyborg P., Bergmann T. K., Jessen N., Simonsen U., and Lykkesfeldt J., “BCPT 2023 Policy for Experimental and Clinical Studies,” Basic and Clinical Pharmacology and Toxicology 133 (2023): 391–396. PubMed

Livak K. J. and Schmittgen T. D., “Analysis of Relative Gene Expression Data Using Real‐Time Quantitative PCR and the 2−ΔΔCT Method,” Methods 25 (2001): 402–408. PubMed

Dragon A. H., Rowe C. J., Rhodes A. M., Pak O. L., Davis T. A., and Ronzier E., “Systematic Identification of the Optimal Housekeeping Genes for Accurate Transcriptomic and Proteomic Profiling of Tissues Following Complex Traumatic Injury,” Methods and Protocols 6, no. 22 (2023): 1–16, 10.3390/mps6020022. PubMed DOI PMC

Aggarwal R., Bhatt D. L., Rodriguez F., Yeh R. W., and Wadhera R. K., “Trends in Lipid Concentrations and Lipid Control Among US Adults, 2007‐2018,” JAMA 328 (2022): 737–745. PubMed PMC

Tybjærg‐Hansen A., Nordestgaard B. G., and Christoffersen M., “Triglyceride‐Rich Remnant Lipoproteins Are More Atherogenic Than LDL per Particle: Is This Important?,” European Heart Journal 44 (2023): 4196–4198. PubMed

Orolin J., Vecera R., Markova I., Zacharova A., and Anzenbacher P., “Differences in Hepatic Expression of Genes Involved in Lipid Homeostasis Between Hereditary Hypertriglyceridemic Rats and Healthy Wistar Rats and in Their Response to Dietary Cholesterol,” Food and Chemical Toxicology 47 (2009): 2624–2630. PubMed

Štolba P., Dobešová Z., Hušek P., et al., “The Hypertriglyceridemic Rat as a Genetic Model of Hypertension and Diabetes,” Life Science 51 (1992): 733–740. PubMed

Klimeš I., Vraana A., Kuneš J., et al., “Hereditary Hypertriglyceridemic Rat: A New Animal Model of Metabolic Alterations in Hypertension,” Blood Pressure 4 (1995): 137–142. PubMed

Pravenec M., Zidek V., Simakova M., et al., “Genetics of Cd36 and the Clustering of Multiple Cardiovascular Risk Factors in Spontaneous Hypertension,” Journal of Clinical Investigation 103 (1999): 1651–1657. PubMed PMC

Cifarelli V. and Abumrad N. A., “Intestinal CD36 and Other Key Proteins of Lipid Utilization: Role in Absorption and Gut Homeostasis,” Comprehensive Physiology 8 (2018): 493–507. PubMed PMC

Ulug E. and Nergiz‐Unal R., “Dietary Fatty Acids and CD36‐Mediated Cholesterol Homeostasis: Potential Mechanisms,” Nutrition Research Reviews 34 (2021): 64–77. PubMed

Zhao L., Li Y., Ding Q., Li Y., Chen Y., and Ruan X. Z., “CD36 Senses Dietary Lipids and Regulates Lipids Homeostasis in the Intestine,” Frontiers in Physiology 12 (2021): 669279. PubMed PMC

Nassir F., Wilson B., Han X., Gross R. W., and Abumrad N. A., “CD36 Is Important for Fatty Acid and Cholesterol Uptake by the Proximal but Not Distal Intestine,” Journal of Biological Chemistry 282 (2007): 19493–19501. PubMed

Sun D., Xiang H., Yan J., and He L., “Intestinal Microbiota: A Promising Therapeutic Target for Hypertension,” Frontiers in Cardiovascular Medicine 9 (2022): 970036. PubMed PMC

Dardi P., Coutinho C. P., de Oliveira S., et al., “Changes in the Intestinal Microbiota Induced by the Postnatal Environment and Their Association With Hypertension,” Pharmacological Research 212 (2025): 107621. PubMed

Siais L., Grangeiro É., Coimbra V., et al., “Correlation Between Firmicutes,

Cao K., Zhang K., Ma M., Ma J., Tian J., and Jin Y., “Lactobacillus Mediates the Expression of NPC1L1, CYP7A1, and ABCG5 Genes to Regulate Cholesterol,” Food Science & Nutrition 9 (2021): 6882–6891. PubMed PMC

Moghaddam M. F., Motoba K., Borhan B., Pinot F., and Hammock B. D., “Novel Metabolic Pathways for Linoleic and Arachidonic Acid Metabolism,” Biochimica et Biophysica Acta 1290 (1996): 327–339. PubMed

Sun D., Lu J., Zhang Y., et al., “Characterization of a Novel CYP1A2 Knockout Rat Model Constructed by Crispr/Cas9,” Drug Metabolism and Disposition 49 (2021): 638–647. PubMed

Guo J., Zhu X., Badawy S., et al., “Metabolism and Mechanism of Human Cytochrome P450 Enzyme 1A2,” Current Drug Metabolism 22 (2021): 40–49. PubMed

Cui H., Gu X., Chen J., et al., “Pregnane X Receptor Regulates the AhR/Cyp1A1 Pathway and Protects Liver Cells From Benzo‐[α]‐pyrene‐induced DNA Damage,” Toxicology Letters 275 (2017): 67–76. PubMed

Kuban W., Haduch A., Bromek E., et al., “The Effect of Maternal High‐Fat or High‐Carbohydrate Diet During Pregnancy and Lactation on Cytochrome P450 2D (CYP2D) in the Liver and Brain of Rat Offspring,” International Journal of Molecular Sciences 25, no. 7904 (2024): 1–17, 10.3390/ijms25147904. PubMed DOI PMC

Tunbridge E. M., Harrison P. J., Warden D. R., Johnston C., Refsum H., and Smith A. D., “Polymorphisms in the Catechol‐O‐Methyltransferase (COMT) Gene Influence Plasma Total Homocysteine Levels,” American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 147B (2008): 996–999. PubMed

Vizzardi E., Bonadei I., Zanini G., et al., “Homocysteine and Heart Failure: An Overview,” Recent Patents on Cardiovascular Drug Discovery 4 (2009): 15–21. PubMed

Postuma R. B. and Lang A. E., “Homocysteine and Levodopa: Should Parkinson Disease Patients Receive Preventative Therapy?,” Neurology 63 (2004): 886–891. PubMed

Kanasaki M., Srivastava S. P., Yang F., et al., “Deficiency in Catechol‐o‐Methyltransferase Is Linked to a Disruption of Glucose Homeostasis in Mice,” Scientific Reports 17 (2017): 1–12. PubMed PMC

Mitschke D., Reichel A., Fricker G., and Moenning U., “Characterization of Cytochrome P450 Protein Expression Along the Entire Length of the Intestine of Male and Female Rats,” Drug Metabolism and Disposition 36 (2008): 1039–1045. PubMed

Yoshinari K., Yoda N., Toriyabe T., and Yamazoe Y., “Constitutive Androstane Receptor Transcriptionally Activates Human CYP1A1 and CYP1A2 Genes Through a Common Regulatory Element in the 5′‐Flanking Region,” Biochemical Pharmacology 79 (2010): 261–269. PubMed

Zemanová N., Anzenbacher P., Zapletalová I., et al., “The Role of the Microbiome and Psychosocial Stress in the Expression and Activity of Drug Metabolizing Enzymes in Mice,” Scientific Reports 10, no. 1 (2020): 1–8. PubMed PMC

Wang S., Wen Q., Qin Y., Xia Q., Shen C., and Song S., “Gut Microbiota and Host Cytochrome P450 Characteristics in the Pseudo Germ‐Free Model: Co‐Contributors to a Diverse Metabolic Landscape,” Gut Pathogens 15 (2023): 1–14. PubMed PMC

Lemmer B., Mattes A., Böhm M., and Ganten D., “Circadian Blood Pressure Variation in Transgenic Hypertensive Rats,” Hypertension 22 (1993): 97–101. PubMed

Jennings B. L., Montanez D. E., May M. E., et al., “Cytochrome P450 1B1 Contributes to Increased Blood Pressure and Cardiovascular and Renal Dysfunction in Spontaneously Hypertensive Rats,” Cardiovascular Drugs and Therapy 28 (2014): 145–161. PubMed PMC

Walker N. J., Gastel J. A., Costa L. T., Clark G. C., Lucier G. W., and Sutter T. R., “Rat CYP1B1: An Adrenal Cytochrome P450 That Exhibits Sex‐Dependent Expression in Livers and Kidneys of TCDD‐Treated Animals,” Carcinogenesis 16 (1995): 1319–1327. PubMed

Leung T. M. and Nieto N., “CYP2E1 and Oxidant Stress in Alcoholic and non‐alcoholic Fatty Liver Disease,” Journal of Hepatology 58 (2013): 395–398. PubMed

Emery M. G., Fisher J. M., Chien J. Y., et al., “CYP2E1 Activity Before and After Weight Loss in Morbidly Obese Subjects With Nonalcoholic Fatty Liver Disease,” Hepatology 38 (2003): 428–435. PubMed

Zong H., Armoni M., Harel C., Karnieli E., and Pessin J. E., “Cytochrome P‐450 CYP2E1 Knockout Mice Are Protected Against High‐Fat Diet‐Induced Obesity and Insulin Resistance,” American Journal of Physiology‐Endocrinology and Metabolism 302 (2012): 532–539. PubMed PMC

Loganathan L., Carlus S. J., and Muthusamy K., “Renin and CYP P450 Gene Variations Significantly Associated With Essential Hypertension: A Prospective Pharmacogenomics Study,” Gene Reports 37 (2024): 102023.

Kim H., Putt D. A., Zangar R. C., et al., “Differential Induction of Rat Hepatic Cytochromes P450 3A1, 3A2, 2B1, 2B2, and 2E1 in Response to Pyridine Treatment,” Drug Metabolism and Disposition 29 (2001): 353–360. PubMed

Zuber R., Anzenbacherová E., and Anzenbacher P., “Cytochromes P450 and Experimental Models of Drug Metabolism,” Journal of Cellular and Molecular Medicine 6 (2002): 189–198. PubMed PMC

Subramanian M., Tam H., Zheng H., and Tracy T. S., “CYP2C9‐CYP3A4 Protein‐Protein Interactions: Role of the Hydrophobic N Terminus,” Drug Metabolism and Disposition 38 (2010): 1003–1009. PubMed PMC

Manda V. K., Avula B., Dale O. R., et al., “PXR Mediated Induction of CYP3A4, CYP1A2, and P‐gp by PubMed

Zhou J., Febbraio M., Wada T., et al., “Hepatic Fatty Acid Transporter Cd36 Is a Common Target of LXR, PXR, and PPARγ in Promoting Steatosis,” Gastroenterology 134 (2008): 556–567.e1. PubMed

Mendoza M. F., Kachur S. M., and Lavie C. J., “Hypertension in Obesity,” Current Opinion in Cardiology 35 (2020): 389–396. PubMed

Bauters T., “Table 31.1, [CYP3A4 Substrates, Inhibitors and Inducers…],” in The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies (Springer, 2019): 229–235, 10.1007/978-3-030-02278-5. PubMed DOI

Taylor C., Crosby I., Yip V., Maguire P., Pirmohamed M., and Turner R. M., “A Review of the Important Role of CYP2D6 in Pharmacogenomics,” Genes 11 (2020): 1–23. PubMed PMC

Ghodke‐Puranik Y. A. and Lamba J. K., “Pharmacogenomics,” in Innovative Approaches in Drug Discovery: Ethnopharmacology, Systems Biology and Holistic Targeting (Academic Press, 2017): 195–234.

NR1I3 Nuclear Receptor Subfamily 1 Group I Member 3 [

Kugler N., Klein K., and Zanger U. M., “MiR‐155 and Other MicroRNAs Downregulate Drug Metabolizing Cytochromes P450 in Inflammation,” Biochemical Pharmacology 171 (2020): 113725. PubMed

Zuo Q., Chen K. L., Arredondo Eve A., et al., “Pathway Preferential Estrogens Prevent Hepatosteatosis due to Ovariectomy and High‐Fat Diets,” Nutrients 13 (2021): 1–15, 10.3390/nu13103334. PubMed DOI PMC

Patel S. B., Graf G. A., and Temel R. E., “Thematic Review Series: Lipid Transfer Proteins: ABCG5 and ABCG8: More Than a Defense Against Xenosterols,” Journal of Lipid Research 59 (2018): 1103–1113. PubMed PMC

Tsiokou V., Kilindris T., Begas E., Kouvaras E., Kouretas D., and Asprodini E. K., “Altered Activity of Xenobiotic Detoxifying Enzymes at Menopause—A Cross‐Sectional Study,” Environmental Research 182 (2020): 109074. PubMed